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The three mammalian RUNX genes have 
evolved distinctive and highly lineage-specific roles in 
development but show evidence of redundant functions in 
oncogenesis where they may function either as oncogenes 
or tumor suppressors according to context [1]. The 
core binding complexes formed by RUNX proteins and 
their cofactor CBFB accomplish their essential roles by 
activating or repressing target gene expression, and these 
processes are regulated by post-translational modification 
and interaction with cofactors. Not surprisingly, RUNX 
regulation also engages the miRNA network [2], as RUNX 
transcriptional regulation orchestrates the expression of 
specific miRNAs, while the expression of the RUNX 
proteins is in turn modulated by miRNA activity. Much of 
this control is exerted through miRNA target sites in the 
RUNX 3’UTRs that are unusually long and divergent in 
sequence, strongly suggesting a role for miRNA regulation 
in lineage-specific aspects of RUNX function. 
The RUNX1(AML1) gene first came to prominence 
in the blood cancer field due to its frequent involvement 
in human leukemia where it is subject to a diverse array 
of chromosomal translocations, of which the archetype 
and most common is the t(8;21) translocation found 
in many cases of acute myeloid leukemia (AML). This 
translocation results in the expression of a fusion protein 
with an N-terminus derived from RUNX1, including the 
Runt DNA binding domain but lacking the C-terminal 
regulatory domain. The truncated RUNX1 is fused to 
the C-terminal moiety of ETO, a zinc finger protein that 
serves to recruit co-repressors to target genes [3]. The 
RUNX1-ETO complex appears to contribute to AML 
development mainly by blocking terminal differentiation. 
While early studies suggested that the fusion protein may 
be a constitutive and dominant negative inhibitor of all 
RUNX targets, more recent studies have shown that AML 
cell viability requires the continued expression of the wild-
type RUNX1 protein from the un-translocated allele as 
well as the RUNX1-ETO fusion protein [4]. It appears that 
leukemic cell survival and growth depends on a critical 
balance between RUNX1 and its fusion oncoprotein 
derivatives.
A general feature of fusion oncoproteins is that 
they assemble modular protein functional domains from 
heterologous proteins to create products that are foreign 
to the cellular regulatory apparatus. Moreover, they are 
expressed from hybrid mRNAs in which the 3’UTR is 
attached to a new 5’ moiety, creating a novel structure 
that is likely to perturb the miRNA regulatory network. 
An interesting example of this phenomenon and its 
importance for leukemia development is provided by 
the recent paper from Zaidi in Oncotarget [5] where the 
authors show that the tumor suppressive miR-29b-1 forms 
a negative feedback loop with the RUNX1-ETO fusion 
protein. This miRNA was first described as a target for 
positive regulation by RUNX3 in gastric cancer cells [6] 
and appears to be down-regulated in t(8;21) cell lines 
where the promoter is bound by RUNX1-ETO and co-
repressors. Significantly, ectopic expression of miR-29b-1 
inhibits cell growth and promotes both apoptosis and 
terminal differentiation [5].
These new findings provoke further questions about 
the dynamics of gene regulation and protein translation. 
For example, the accumulation of RUNX1-ETO protein 
in AML cells argues that the demonstrated miR-29b-1 
negative feedback through its 3’UTR is not fully dominant, 
even though RUNX1 is also detectable on its promoter and 
is presumably driving expression at some level in AML 
cells [5]. This scenario invites consideration of the recent 
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Figure 1: The figure depicts a model for the subversion 
of miRNA regulation due to the t(8;21) translocation 
in AML and expression of the RUNX1-ETO fusion 
oncoprotein. RUNX1 and RUNX1-ETO respectively 
activate and repress transcription of tumor suppressor pre-
miRNAs exemplified by miR-29b-1 (ref 5). The effect 
of RUNX1-ETO repression may be reinforced by over-
expression of the 3’ UTR of ETO under control of the RUNX1 
promoter, creating a sponge for miR-29b-1 and other tumor 
suppressive miRNAs (ref 7).
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prediction that the t(8;21)-specific over-expression of the 
ETO 3’UTR under the control of the RUNX1 promoter 
creates a miRNA sponge [7]. According to this model, 
by its presence in molar excess the sponge overwhelms 
the negative regulatory activity of miR-29b-1 and other 
miRNAs with tumor suppressive potential. Moreover, as 
illustrated this process could operate synergistically with 
direct transcriptional repression of miRNAs by RUNX1-
ETO (see Figure 1). 
Studies of end-stage t(8;21) leukemias are revealing 
an intricate landscape of genetic and epigenetic changes 
[8]. Post-transcriptional changes involving the miRNA 
apparatus adds a further dimension to this complex 
picture. Moreover, the t(8;21) translocation often arises 
in utero long before the appearance of AML and requires 
secondary mutations to reveal its full oncogenic potential 
in model systems [3]. If new broadly effective therapies 
are to be generated it will be important to distinguish the 
direct effects of RUNX1-ETO such as those described 
[5] from the stochastic events that drive leukemic cell 
expansion and progression.
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